A.Y.H. Lu's scientific contributions

Citations

... Dose-limiting toxicities pose a major challenge in drug development (1). Decades of pharmacogenomic research have identified host alleles responsible for variable drug metabolism, yet clinical implementation has lagged due to persistent unexplained variability in toxicity (2,3). The gut microbiome complements and extends host pathways of drug metabolism, with depletion of hundreds of pharmaceuticals following in vitro incubation with gut strains (4,5). ...